No profile data available.
Vertex Pharmaceuticals Incorporated (VRTX) is a healthcare company in the lung treatment pharmaceuticals industry, based in Boston, United States, with about 6,400 full-time employees.
It reported revenue of $12.00 billion for fiscal year 2025, up 8.9% from fiscal year 2024, and net income of $3.95 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $3.33 billion, up 12.5% from a year before. United States was its largest region in fiscal year 2025, with 63% of revenue. Its market capitalization was $129.20 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Vertex Pharmaceuticals reported $12.00 billion in revenue for fiscal year 2025, up 8.9% from $11.02 billion in fiscal year 2024. In Q2 2026 revenue was $3.33 billion.
United States: 63% of revenue by region in fiscal year 2025, followed by Europe (29%).
$129.20 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Innoviva, Inc. (INVA), Upstream Bio, Inc. (UPB), Savara Inc. (SVRA), Gyre Therapeutics, Inc. (GYRE).